VERTEX PHARMACEUTICALS INC / MA Derivative Asset, Fair Value, Amount Offset Against Collateral
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Derivative Asset, Fair Value, Amount Offset Against Collateral of $6.09 million as of 2016-09-30, per its 10-Q filed 2016-10-31.
Discontinued › Notes › Offsetting › Offsetting Derivative Assets
us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral · last filed 2016-10-31
- 2016-09-30: Derivative Asset, Fair Value, Amount Offset Against Collateral $6.09M.
- 2016-06-30: Derivative Asset, Fair Value, Amount Offset Against Collateral $4.17M.
- 2016-03-31: Derivative Asset, Fair Value, Amount Offset Against Collateral $0.00.
- 2015-12-31: Derivative Asset, Fair Value, Amount Offset Against Collateral $4.87M.
| Period end | Derivative Asset, Fair Value, Amount Offset Against Collateral |
|---|---|
| 2016-09-30 | $6.09M 10-Q · filed 2016-10-31 |
| 2016-06-30 | $4.17M 10-Q · filed 2016-08-01 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-03 |
| 2015-12-31 | $4.87M 10-Q · filed 2016-10-31 |
| 2015-09-30 | $2.58M 10-Q · filed 2015-10-30 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-04 |
| 2015-03-31 | $2.32M 10-Q · filed 2015-05-04 |
| 2014-12-31 | $2.01M 10-K · filed 2016-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |